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Background: In this first study conducted after the introduction of artemisinin-combination therapy (ACT), the
major objective was to evaluate Plasmodium falciparum genetic diversity and multiplicity of infection in isolates
from Congolese children between one and nine years of age enrolled and followed up for one year. The secondary
objective was to characterize the msp2 profiles of P. falciparum isolates collected from successive malaria episodes
in ten children who had four or more clinical episodes during the follow up.
Methods: Three-hundred and thirteen children residing in southern part of Brazzaville participated in this study.
Blood samples were obtained from all children at enrollment and checked for P. falciparum infection. Based on the
one year follow-up data, two clinical groups were considered according to the number of malaria episodes
presented over the follow up period: “protected”(children who did not experience any episode) and “unprotected”
(those who experienced more that two episodes). Therefore, the msp2 genetic diversity of P. falciparum isolates
collected at enrollment in the two groups was characterized by allele-specific nested PCR and compared. The msp2
profiles of P. falciparum isolates collected from successive malaria episodes was also characterized by allele-specific
nested PCR.
Results: Forty-three percent of FC27 and fifty-seven percent of 3D7 in protected vs fifty-six percent of FC27 and
forty-four percent of 3D7 in isolates from unprotected children were detected. Seven and two alleles belonging to
the FC27, and six and three alleles belonging to 3D7 families were distinguished in isolates from protected and
unprotected children respectively. The mean multiplicity of infection (MOI) values at inclusion for the msp2 locus
was 1.29 and 1.43 for protected and unprotected children respectively. 43 isolates were obtained from the ten
children who had four or more clinical episodes during the follow up. A total of 63 alleles or fragments
corresponding to 57% (36/63) FC27 and 43% (27/63) 3D7 were detected. The variant 400bp of FC27 was the most
prevalent. 46% (20/43), 42% (18/43), 2% (1/43) and 2% (1/43) of isolates were found to have 1, 2, 3 and 4 parasite
genotypes respectively and the mean MOI was 1.78.
Conclusion: This study shows that the introduction of ACT in the Republic of Congo has reduced the MOI but not
the genetic diversity of P. falciparum isolates from children living in Southern districts of Brazzaville.
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The last decade, tremendous concerted efforts have been
made to control malaria [1], and the success observed
in some countries (Tanzania, Ethiopia) has raised hope
in the global community. This decline in the disease
burden with 655,000 deaths in 2011 could be attributed
to control interventions like insecticide-treated nets, in-
door insecticide spraying, deployment of artemisinin-
combination therapy (ACT) and intermittent preventive
treatment for pregnant women [2,3].
The challenges facing all those fighting malaria are the
elaboration of efficient tools that could be used in any
endemic country and reached all the affected population.
In that perspective, malaria vaccine would be the best
weapon if efficient and affordable by poor people [4,5].
In areas where malaria is endemic, immunity to Plas-
modium falciparum malaria develops slowly and is
hardly ever complete. This phenomenon is explained by
the fact that many parasite strains, differing in the
sequences of key protective antigens circulate within any
given malaria endemic area [6]. The genetic and anti-
genic diversity of P. falciparum strains has been reported
as a major obstacle for the development of an effective
malaria vaccine. Indeed, it has been shown geographical
diversity of P. falciparum strains in asymptomatic and
symptomatic isolates [7] and it is quite difficult to iden-
tify the best immune targets that will lead to the malaria
vaccine, eventually. There is a need to understand why
some children do not develop malaria episodes while
others have repeatedly malaria attacks under the same
malaria and socio-economic exposure. Human genetic
background like sickle cell trait carriage, blood group
and other mutations have been reported to influence sus-
ceptibility to clinical malaria [8,9] of some exposed indi-
viduals but the mechanisms remain poorly understood.
The merozoite surface protein−2 (MSP-2) of P. falcip-
arum is considered as a good candidate for inclusion
into a malaria vaccine. Several studies have reported the
relationship between protection and humoral immune
responses to MSP-2 antigens [10,11]. Moreover, mero-
zoite surface protein-2 gene (msp2) is also commonly used
as a single marker for the molecular characterization of
field malaria parasites [12], because it appears to be more
or at least as equal reliable as the merozoite surface
protein-1 (msp1) marker [6,13]. These genes are repre-
sented as a single copy on P. falciparum genome [14]
and high degree of polymorphism has been reported in
the block 2 for msp1 gene [15] and in the central variable
region for msp2 gene [14]. Typing of these different poly-
morphic P. falciparum genome regions have permitted
to determine malaria infection indicators e.g. diversity of
P. falciparum strains and multiplicity of infection (MOI),
which may contribute to the description of malaria situ-
ation in a given location.Against this background, many sub-Saharan African
countries cannot, because of limited resources, report
updated data on the malaria situation and specifically on
the genetic diversity of malaria parasites circulating in
their areas. These data would assist in identifying the
most appropriate strategies for control and also to evalu-
ate the impact of control interventions.
In the Republic of Congo, since 2009, the Central Af-
rica Network on Tuberculosis, HIV/AIDS and Malaria
(CANTAM) has initiated baseline epidemiological stud-
ies for collecting in vivo and in vitro data on sensitivity
to anti-malarials and characterization of malaria para-
sites infecting children living in Brazzaville. The major
objective of the present study carried out in the southern
part of Brazzaville was to evaluate P. falciparum genetic
diversity and multiplicity of infection in isolates from
children who did not have any malaria episode (consid-
ered as “protected” against clinical malaria) and children
who presented three or more uncomplicated malaria epi-
sodes (considered as “non-protected”) during one year
follow-up. The secondary objective was to characterize
the msp2 profiles of P. falciparum isolates collected from
successive malaria episodes in ten children who had four
or more clinical episodes during the follow up.Methods
Study site
The study was conducted in Madibou, a semi-urban dis-
trict located in a Southern part of Brazzaville [16], where
malaria transmission is high and perennial with an ento-
mological inoculation rate (EIR) of 22.5 infective bites/
person/year estimated several years ago [17,18].Ethical clearance
This study was approved by the Institutional Ethics
Committee for Research on Health Sciences. Written
informed consent was given by parents or guardians of
children who participated in the study.Study population
Children between one and nine years of age and per-
manent residents of the study area were enrolled in a co-
hort study for malaria surveillance [19]. Inclusion
criteria were absence of clinical malaria in the last two
weeks and at least one week after enrolment, and with
an axillary temperature of <37.5°C and parasite density
<5,000 parasites/μl of blood. Recruitment was done from
April to June 2010. At inclusion, after clinical examin-
ation by the physician, thick and thin blood smears were
made from each child and whole blood were also col-
lected for subsequent analyses including DNA extraction
and haemoglobin genotyping. Parasite density was
Ibara-Okabande et al. Malaria Journal 2012, 11:410 Page 3 of 7
http://www.malariajournal.com/content/11/1/410determined and genomic human and parasite DNA were
analysed as described by Koukouikila-Koussounda et al.
[19]. Then, children were passively followed up during
one year. Children with fever or any disease symptoms
were asked to go to the health care, where appropriate
standard care were provided. In case of malaria, a blood
sample was collected, parasite density determined and
treatment with artesunate-amodiaquine or artemether-
lumefantrine provided by the clinician. During the fol-
low-up, 141 children did not present any clinical malaria
episode and, although it is known that there is no sterile
protection against malaria, these children were consid-
ered as “protected”. Other children presented several
malaria attacks and were considered as “unprotected”.Plasmodium falciparum msp2 genotyping
Genotyping of P. falciparum parasites was performed
with nested PCR assays based on the amplification of
msp2 as described in details elsewhere [20]. The variable
block 2 was amplified to distinguish allelic families 3D7
and FC27. The amplified products from the nested reac-
tion were separated using 2% agarose gel (PeqLab,
Erlangen, Germany), and visualized under ultraviolet
(UV) trans-illumination. A 100 base pairs (bp) DNA lad-
der marker (Invitrogen, Karlsruhe, Germany) was used
to determine the size of bands. The size polymorphism
in each allelic family was estimated assuming that one
band represented one amplified PCR fragment derived
from a single copy of msp2 gene. Determination of
haemoglobin type (AA, AS and SS) in this cohort of chil-
dren was performed as described by Koukouikila-
Koussounda et al. [19].Plasmodium falciparum msp2 allele types distribution and
multiplicity of infection
The prevalence of the different msp2 alleles was deter-
mined as the presence of PCR products in the total
number of msp2 amplified bands. The MOI was defined
as the mean number of P. falciparum genotypes per
infected individual. It was calculated as the quotient of
the total number of P. falciparum msp2 genotypes and
the number of PCR positive samples.Statistical analysis
Statistical analysis was performed using R software, ver-
sion 2.12. Frequency of msp2 allelic families in both
groups (“protected” vs “unprotected”) was compared
using a Chi 2 test. Comparisons of the geometric mean
parasite density (GMPD) between the two groups as well
as that of the MOI were made using the Kruskal-wallis
tests. Differences were considered statistically significant
at P value < 0.05.Results
Description of the recruited children
Of the 313 samples collected at inclusion, 28 were
detected with P. falciparum parasites representing 9%
and 24 sub-microscopic infections were detected by PCR.
Therefore, a prevalence of 16% (52/313) of P. falciparum
infections was found. Plasmodium falciparum was the
only species detected. Children enrolled in this study
were aged from one to nine years old and were grouped
into three groups (0, 1 to 2, ≥3 according to the number
of malaria attacks presented during the one year follow-
up). It was found that 10 children had more than four
malaria attacks. As defined in the Methods section, chil-
dren who did not present any malaria attacks were con-
sidered as “protected” against clinical malaria and those
with more than two clinical episodes as unprotected
(Table 1). The GMPD was found to be significantly dif-
ferent between these two groups, being lower in the
group of protected children and higher in the group of
unprotected children (P=0.01).
Genetic diversity and allelic frequency
The band sizes of msp2 FC27 alleles ranged from 260
to 540 bp and that of 3D7 alleles ranged from 180 to
480 bp. The prevalence of FC27 and 3D7 family repre-
sented 45% and 55% respectively in overall isolates from
asymptomatic children. Considering the two groups, pro-
tected or unprotected, we found 43% FC27 and 57% 3D7
in protected vs 56% FC27 and 44% 3D7 in isolates from
unprotected children. 7 and 2 alleles belonging to the
FC27 family, and 6 and 3 alleles belonging to the 3D7
family were distinguished in isolates from protected and
unprotected children respectively as shown in Figures 1
and 2.
Multiplicity of P. falciparum infection
The mean MOI values at inclusion for the msp2 locus
were 1.29 and 1.43 for protected and unprotected chil-
dren respectively (p<0.047).
Characterization of P. falciparum isolates from successive
malaria episodes
The 10 children who presented four or more clinical
malaria episodes during the follow up were selected for
the characterization of all isolates collected during these
attacks. The geometric mean parasite density from all suc-
cessive malaria episodes was 22,964 parasites per micro-
liter of blood (p/μl), ranging from 160 to 473,882 p/μl. A
total of 43 samples were analysed. In order to distinguish
between recrudescence and new infection when two
malaria episodes occurred at a too short period (less
than 45 days), two additional P. falciparum molecular
markers were used, msp1 and glutamate-rich protein
(glurp). No recrudescent pattern was found. Using msp2
























Protected (141) 3 ± 2.57 9 684* 9 12.76 111 30
1 to 2 malaria attacks (141) 5 ± 2.55 14 1,310 13 19.15 119 21
Unprotected (31) 5 ± 2.33 5 3,890* 2 22.58 23 7
P-value NS 0.007 NS NS NS
*p-value = 0.01.
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to 43% 3D7 and 57% FC27 were detected from the 43 dif-
ferent episodes. A number of 27 (11 different allele types)
and 36 (10 different allele types) fragments were identi-
fied to belong to 3D7 and FC27 allelic families respect-
ively. However, the variant 400bp of FC27 was the most
prevalent in clinical isolates (Table 2).
With regard to the number of isolates containing one,
two, three and four different genotypes, 20/43 (46%), 18/
43 (42%), 1/43 (2%) and 1/43 (2%) were found to have
one, two, three and four parasite genotypes, respectively.
Three samples were not identified to any of the 3D7 or
FC27 allelic family despite being repeatedly amplified.
This might be due to a mutation in the annealing region
of the primers. The mean MOI for these ten children
was 1.0 at inclusion (asymptomatic phase) and 1.78 for
the all clinical episodes.
Discussion
In malaria endemic areas, people are exposed to diverse
P. falciparum strains and this contributes to the develop-
ment of natural immunity including clinical and parasite-
immunity. Determining P. falciparum genetic diversity
and MOI from field samples may be useful and help-
ful indicators to describe malaria infection in a place
and to relate to the level of immunity at the time of
infection [21].
This study carried out in 2009 in Southern part of
Brazzaville after the introduction of ACTs showed that
P. falciparum genetic diversity in isolates from CongoleseFigure 1 Distribution of FC27 alleles of P. falciparum msp2
gene in isolates from Congolese children at enrollment.children did not change and remains at about 20 msp2
alleles. To the best of our knowledge, this study is the
first to describe P. falciparum infections in clinical cases
in Congolese children after the introduction of ACTs in
the Republic of Congo. Based on the one year follow up
of children, two clinical groups were considered accord-
ing to the number of malaria episodes presented over
the study period: “protected” and “unprotected” referring
to the absence of malaria episodes or more than two
malaria episodes respectively. Interestingly, msp2 genetic
diversity in the “protected” group was higher compared
to the unprotected children. A possible explanation
could be the better control of Plasmodium falciparum
strains by protected children under a threshold leading
to fever [22].
The genetic diversity of the msp2 is limited in both
clinical groups at asymptomatic phase. However, it is
observed that the 3D7 allelic family, which is the most
prevalent in the general population [19] is also the most
prevalent in protected children, whereas the FC27 allelic
family predominated in the unprotected group, pointing
out that FC27 allelic types are the less successful con-
trolled strains in unprotected children and probably
acquisition of natural semi-immunity in this population
has to include the control of these specific strains. In
many countries (Tanzania, Burkina Faso, Malawi and
Uganda), Mwingira et al. [23] showed that the 3D7
family was the most predominant in clinical isolates.Figure 2 Distribution of 3D7 alleles of P. falciparum msp2 gene
in isolates from Congolese children at enrollment.
Table 2 Profiles of P. falciparum msp2 genotypes during successive episodes
Episode1 Episode2 Episode3 Episode4 Episode5 Episode6
Child1 A600 A480 A500+B300 B280
Child2 A600+B400 A380+A480 – A500
Child3 A500 A500 A480+A520 B380 B380 B500
Child4 A300 A350 A400 A300+B280
Child5 A380 A400+B300 B180 –
Child6 A280+A300+B380+B400 A280+B450 A350+A400 A300
Child7 A400+B450 A300+B420 A300+B450 B300
Child8 A350+B250 A350+B300 A320+B280 B220+B450
Child9 A350 A400+B350 A400+B300 A450
Child10 – B380 A300+B300 A300+A400+B300 B320
Note: A and B represent alleles for FC27 and 3D7 families respectively.
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family was found to be the most predominant parasite
allelic types. This difference can be explained by the fact
that genetic diversity of P. falciparum differs according
to geographic areas, and the level of transmission [26].
With regard to the parasite density, during the asymp-
tomatic phase, a significantly higher parasite density was
observed in unprotected children. These findings are in
agreement with another study suggesting the association
of asymptomatic parasitaemia of higher parasite density
with a higher risk of symptomatic malaria in children
[25]. Considering the molecular epidemiological studies
carried out in this population before the introduction of
ACT [27,28], the level of parasitaemia in clinical cases is
reduced in the present study. This suggests that inter-
mittent treatment of asymptomatic infections with a
high parasitaemia would be an efficient tool of preventing
clinical episodes of malaria in childhood. To implement
such an intervention, the definition of a parasitaemia
threshold for Congolese patients [22], which has not
been defined, would be imperative.
The MOI is considered to be a key indicator of malaria
infection in humans and may reflect to some degree
malaria transmission and immunity [6]. The mean MOI
was slightly higher in unprotected children and this
result correlates with the higher parasite density in
unprotected children with asymptomatic infection. This
finding could be interpreted as a reduce acquired im-
munity in unprotected children confirming a higher risk
of occurrence of clinical malaria [6,21,29]. However, the
mean MOI in clinical isolates is lower than expected
from previous studies conducted in the same area and
the same age group. It is important to note the low MOI
of about 1.3 and the high number of children harbouring
one malaria genotype in the study group with regard to
the level of malaria transmission [19] This is different to
what was reported from other endemic areas in Central
Africa [23,30]. This could be explained by the massivedistribution of impregnated mosquito nets by the gov-
ernment and supporting agencies and the deployment
of artemisinin-combination therapy in the country. As a
result, there has been a decrease of the burden of malaria
parasites, reflected in lower parasite densities, but this
did not influence the diversity of parasites in circulation.
In a second step of this study, P. falciparum infections
during successive clinical attacks in unprotected children
have been characterized by analysing each isolate using
three molecular markers: msp1, msp2 and glurp when
necessary [23]. The discrimination between recrudes-
cence and new infections has been carefully analysed. It
appears that the successive clinical episodes experienced
by each child were caused by genetically distinct parasite
populations. This gives a confirmation that each episode
was a true one instead of being a recrudescence and only
one child for one episode was identified as recrudes-
cence. Therefore, we can claim that malaria episodes in
these children were caused by new inoculated parasites.
These findings are in line with previous reports from
Soudan, Senegal, and Gabon [31-33]. It is worth noting
that the FC27 fragment of 400bp, which was the most
prevalent in clinical episodes of malaria, was also observed
with a high frequency in other studies among symp-
tomatic malaria children [34,35]. This may indicates an
association between this FC27 allelic type and clinical
episodes, hence predicts a possible candidate antigene
that can be considered in designing malaria vaccine.
As a conclusion, this study shows that the introduc-
tion of ACT in the Republic of Congo has reduced
the multiplicity of infection but not the genetic diver-
sity of P. falciparum isolates from children living in
Southern districts of Brazzaville. It also points out that
children exposed to the same malaria transmission and
socio-economic conditions might have different suscep-
tibility to malaria infections. The two groups described
here are important for designing additional studies to
investigate human and parasite genetic factors that
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aria in this area.
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